Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07545811 · ClinicalTrials.gov registry record · Phase 1
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Janux Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT07545811: Recruiting Phase 1 study, sponsored by Janux Therapeutics.
NCT07545811 is a Phase 1 study that is actively recruiting participants, run by Janux Therapeutics. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07545811, a Phase 1 study, is actively recruiting participants, sponsored by Janux Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- BIOLOGICAL JANX014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT07545811 shows while recruiting
NCT07545811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which JANX014 is the first listed.
NCT07545811 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07545811 about?
NCT07545811 is a clinical study titled "Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer". This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT07545811?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2026-04-15. Estimated completion is 2029-03.
What interventions are being tested in trial NCT07545811?
The interventions under investigation include: JANX014 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07545811?
This trial is sponsored by Janux Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07545811's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI